Alzheimer's Research

“Florida Alzheimer’s Disease Research Center (ADRC) Clinical Core” (Protocol #15-29-H-06)

Do you want to participate in a study which is evaluating the usefulness of brain imaging studies, tests of blood and spinal fluid, together with measurements of memory, thinking and daily functioning in the identification of Alzheimer’s disease at an early stage?

The Wien Center, in collaboration with several universities in Florida, is studying how to best use brain images, blood tests and memory evaluations to identify the earliest stages of Alzheimer’s Disease.

You may qualify for this study if you are over 60 years of age and have mild Alzheimer’s Disease or are over 70 years of age and have normal memory or mild memory loss. You will be required to have one (1)  PET scan, two   (2) MRI scans, one (1) blood draw and memory and thinking tests throughout the study. You will be reimbursed for your time.

For more information, please contact Dr. Maria Greig at (305) 674-2121, extension 54480, or at mgreig@msmc.com or call (305) 674-2037.


“Randomized, Double-Blind, Placebo Controlled, Multi-Center Registration Trial to Evaluate the Efficacy and Safety of TTP488 in Patients with Mild Alzheimer’s Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine” (Protocol #15-18-H-03)

Do you want to take part in a study to determine whether an experimental drug can keep your memory and thinking from declining?

The Alzheimer’s Disease Cooperative (ADCS) is testing a drug called “TTP488” to determine whether this drug will help your memory and thinking  from declining, as occurs with Alzheimer’s Disease.

You may qualify for this study if you are over 50 years of age and have mild Alzheimer’s Disease.  The study drug or a sugar pill (placebo) will be given to you over a period of 18 months.  You will be required to have 3 PET scans and 2 MRI scans of your brain.  You will have memory and thinking tests throughout the study.  You will be reimbursed for your time.

For more information, please call (305) 674-2037.


Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (The A4 Study) (Protocol #14-02-H-01)

Do you want to participate in a study to determine whether an experimental vaccine can keep your memory and thinking from declining?

Eli Lilly has a new drug called “solanezumab” which targets a harmful substance in your brain, known as Amyloid.  Amyloid plaques are one of the hallmark features of Alzheimer’s Disease.  If solanezumab stops the buildup of these Amyloid plaques in your brain, it may help your memory and thinking from declining with age, as occurs with Alzheimer’s Disease.

You may qualify for this study if you are between 65 and 85 years of age and have “normal” memory and thinking skills.  The study drug will be given every 4 weeks via an intravenous infusion.  You will also be required to have 2 PET scans and show the amount of Amyloid in your brain and 4 MRI scans of your brain.  You will have memory and thinking tests every year.  You will be reimbursed for your time.

For more information, please contact Dr. Maria Greig at (305) 674-2121, ext 54480, via e-mail at mgreig@msmc.com, or call (305) 674-2037.


A Phase III, Randomized, Placebo Controlled, Parallel- Group, Double-Blind Clinical Trail to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease (Prodromal AD) (Protocol #13-29-H-11)

Do you want to take part in a study to determine the effectiveness of a new medication in the treatment of Alzheimer’s Disease symptoms? MK7622 is a drug designed to be taken in conjunction with Donepezil that is aimed to reduce symptoms commonly found in Alzheimer’s Disease. You will be allowed to continue taking your current medications if you enroll in this study.

This study is sponsored by Merck & Co. and the Wien Center. You may qualify for this study if you are in good general health, have a diagnosis of Alzheimer’s Disease, currently take Donepezil, and are between the ages of 55-85.

If you qualify, you will be given either a pill of active study drug (MK7622) or a placebo (“fake” medication), so that scientists can study the effect of the medication. You will visit the clinic a total of 10 times, including a MRI scan of your brain, blood work, questionnaires, and memory testing. You will be reimbursed for your time.

For more information, please call (305) 674-2037.


State of Florida Brain Bank – Searching for the Answers (Protocol #97-82-H-11)

Brain Donation is one very important way of confirming the diagnosis of Alzheimer’s disease or other forms of dementia. Brain Donation is crucial for learning more about how to diagnose and treat Alzheimer’s disease. If someone near and dear to you has been diagnosed to have Alzheimer’s disease or memory problems, the State of Florida Brain Bank can make all the arrangements to facilitate donation of the brain for confirming the diagnosis and for research. Individuals who are in the earliest stages of Alzheimer’s Disease, and those with a pre-Alzheimer condition known as Mild Cognitive Impairment are particularly important for this research. Normal brain tissue, for comparison purposes is difficult to get but is also very important for research. Individuals who are over the age of 65 and have normal memory can donate their brains for research through this program, after getting a comprehensive neurological examination and an MRI scan of the brain.

For those who participate in this study:

  • At the time of death we will arrange for the transportation and removal of the brain, at no cost.
  • We will provide a detailed pathological report, at no cost to you.

If you have any further questions or need more details about this study, please call Dr. Maria Teresa Greig at (305) 674-2018 or call (305) 674-2037.


Memory Screening Studies on Healthy Aging (Protocol #01-61-H-08)

Are you worried that your memory is not what it used to be? Take advantage of a free memory screening to determine if further evaluation is needed. Participants must be at least 50 years of age. Screenings are available at:

Mount Sinai Medical Center
4302 Alton Road, #650
Miami Beach, FL 33140
Limited space · By appointment only · Please call (305) 674-2037


 

 

“A Phase 2a Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer’s Disease” (ADCS ADC-049) (Protocol #15-10-H-02)

Do you want to take part in a study to determine whether an experimental drug can keep your memory and thinking from declining?

The Alzheimer’s Disease Cooperative (ADCS) is testing a drug called “AZDd-0530” which may protect connections in your brain from Alzheimer’s Disease.  The ADCS is also studying whether this drug will help your memory and thinking from declining, as occurs with Alzheimer’s Disease.

You may qualify for this study if you are between 55 and 85 years of age and have mild Alzheimer’s Disease.  The study drug or a sugar pill (placebo) will be given to you over a period of one year.  You will be required to have 3 PET Scans and 2 MRI scans of your brain.  You will have memory and thinking tests throughout the study.  Two lumbar punctures will be optional procedures.  You will be reimbursed for your time.

For more information, please call Rosemarie Rodriguez at (305) 674-2121 extension 56771 or via e-mail at Rosemarie.Rodriguez@msmc.com.